{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:06:28Z","timestamp":1789596388503,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA 023074-34"],"award-info":[{"award-number":["P30 CA 023074-34"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00520-020-05466-1","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T23:15:31Z","timestamp":1587683731000},"page":"187-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors"],"prefix":"10.1007","volume":"29","author":[{"given":"Alyssa","family":"Streff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Chu-Pilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Stopeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavani","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"5466_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"R Siegel","year":"2017","unstructured":"Siegel R, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"5466_CR2","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3747\/co.2007.151","volume":"14","author":"C Derzko","year":"2007","unstructured":"Derzko C, Elliott S, Lam W (2007) Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 14(Suppl 1):S20\u2013S40","journal-title":"Curr Oncol"},{"key":"5466_CR3","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra023246","volume":"348","author":"IE Smith","year":"2003","unstructured":"Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431\u20132442","journal-title":"N Engl J Med"},{"key":"5466_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","volume":"20","author":"J Baumgart","year":"2013","unstructured":"Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS (2013) Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause. 20:162\u2013168","journal-title":"Menopause."},{"key":"5466_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","volume":"34","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD, Leach CR, Henry NL, Enry KS, Mackey HT et al (2016) American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care guideline. J Clin Oncol 34:611\u2013635","journal-title":"J Clin Oncol"},{"key":"5466_CR6","doi-asserted-by":"crossref","unstructured":"(2013) Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause 20:888\u2013902","DOI":"10.1097\/GME.0b013e3182a122c2"},{"key":"5466_CR7","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","volume":"33","author":"MF Goetsch","year":"2015","unstructured":"Goetsch MF, Lim JY, Caughey AB (2015) A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 33:3394\u20133400","journal-title":"J Clin Oncol"},{"key":"5466_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1097\/AOG.0000000000000283","volume":"123","author":"MF Goetsch","year":"2014","unstructured":"Goetsch MF, Lim JY, Caughey AB (2014) Locating pain in breast cancer survivors experiencing dyspareunia: a randomized controlled trial. Obstet Gynecol 123:1231\u20131236","journal-title":"Obstet Gynecol"},{"key":"5466_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-016-3827-7","volume":"157","author":"E Sulaica","year":"2016","unstructured":"Sulaica E, Han T, Wang W, Bhat R, Trivedi MV, Niravath P (2016) Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat 157:203\u2013210","journal-title":"Breast Cancer Res Treat"},{"key":"5466_CR10","unstructured":"Farrell R (2016) ACOG Committee opinion number 659"},{"key":"5466_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/annonc\/mdj127","volume":"17","author":"A Kendall","year":"2006","unstructured":"Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584\u2013587","journal-title":"Ann Oncol"},{"key":"5466_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3109\/13697137.2010.529967","volume":"14","author":"G Pfeiler","year":"2011","unstructured":"Pfeiler G, Glatz C, K\u00f6nigsberg R, Geisendorfer T, Fink-Retter A, Kubista E, Singer CF, Seifert M (2011) Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric. 14:339\u2013344","journal-title":"Climacteric."},{"key":"5466_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JOP.2011.000352","volume":"8","author":"S Wills","year":"2012","unstructured":"Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, Hayes DF, Decker DA (2012) Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 8:144\u2013148","journal-title":"J Oncol Pract"},{"key":"5466_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10549-014-2930-x","volume":"145","author":"G Donders","year":"2014","unstructured":"Donders G, Neven P, Moegele M, Lintermans A, Bellen G, Prasauskas V, Grob P, Ortmann O, Buchholz S (2014) Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor\u00ae) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase in clinical study. Breast Cancer Res Treat 145:371\u2013379","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"5466_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","volume":"3","author":"ME Melisko","year":"2017","unstructured":"Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S et al (2017) Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitor for early-stage breast cancer: a randomized clinical trial. JAMA Oncol 3(3):313\u2013319","journal-title":"JAMA Oncol"},{"key":"5466_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/1055-9965.EPI-09-0643","volume":"19","author":"JM Faupel-Badger","year":"2010","unstructured":"Faupel-Badger JM, Fuhrman BJ, Xu X, Falk RT (2010) Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens. Cancer Epidemiol Biomark Prev 19:292\u2013300","journal-title":"Cancer Epidemiol Biomark Prev"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05466-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05466-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05466-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T23:54:01Z","timestamp":1619135641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05466-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5466"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05466-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"24 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Alyssa Streff and Michelle Chu-Pilli report no conflict of interest.Dr. Alison Stopeck reports grants and personal fees from Amgen, personal fees from Novartis, personal fees from Biothera, personal fees from Pfizer, personal fees from AstraZeneca, grants from Seattle Genetics. None of these funding sources are involved\/overlap with the current submitted trial.Dr. Pavani Chalasani reports research funding from Pzifer, advisory boards for Nanostring, Heron therapeutics, Astrazeneca, Amgen, Bayer, Novartis. None of these funding sources are involved\/overlap with the current submitted trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}